Susan M Domchek

List of Publications by Citations

315 papers	23,541 citations	74 h-index	147 g-index
346 ext. papers	28,826 ext. citations	8.5 avg, IF	6.44 L-index

#	Paper	IF	Citations
315	Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. *New England Journal of Medicine*, **2017**, 377, 523-533	59.2	1405
314	Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. *Lancet, The*, **2010**, 376, 235-44	40	1395
313	Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. *Journal of Clinical Oncology*, **2015**, 33, 244-50	2.2	1171
312	Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. *JAMA - Journal of the American Medical Association*, **2010**, 304, 967-75	27.4	993
311	Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. *Journal of the National Cancer Institute*, **2009**, 101, 80-7	9.7	650
310	Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. *Cancer*, **2003**, 97, 2972-7	6.4	589
309	Gene-panel sequencing and the prediction of breast-cancer risk. *New England Journal of Medicine*, **2015**, 372, 2243-57	59.2	587
308	Breast-cancer risk in families with mutations in PALB2. *New England Journal of Medicine*, **2014**, 371, 497-506	59.2	576
307	Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. *Journal of Clinical Oncology*, **2008**, 26, 1331-7	2.2	465
306	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. *Nature Genetics*, **2013**, 45, 371-84, 384e1-2	36.3	422
305	Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). *Cancer Epidemiology Biomarkers and Prevention*, **2012**, 21, 134-47	4	411
304	American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility. *Journal of Clinical Oncology*, **2015**, 33, 3660-7	2.2	360
303	Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. *Journal of Clinical Oncology*, **2005**, 23, 7804-10	2.2	339
302	Cancer yield of mammography, MR, and US in high-risk women: prospective multi-institution breast cancer screening study. *Radiology*, **2007**, 244, 381-8	20.5	299
301	Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. *Lancet Oncology, The*, **2006**, 7, 223-9	21.7	291
300	Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. *JAMA - Journal of the American Medical Association*, **2015**, 313, 1347-61	27.4	286
299	A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. *Nature Genetics*, **2010**, 42, 885-92	36.3	276

298	International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers. *International Journal of Cancer*, **2008**, 122, 2017-22	7.5	268
297	Breast cancer risk among male BRCA1 and BRCA2 mutation carriers. *Journal of the National Cancer Institute*, **2007**, 99, 1811-4	9.7	246
296	CDK 4/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer: phase II activity, safety, and predictive biomarker assessment. *Clinical Cancer Research*, **2015**, 21, 995-1001	12.9	243
295	Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. *American Journal of Human Genetics*, **2008**, 82, 937-48	11	218
294	CD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patients. *Science Translational Medicine*, **2012**, 4, 134ra62	17.5	216
293	Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells. *Clinical Cancer Research*, **2010**, 16, 3485-94	12.9	212
292	Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes. *Clinical Cancer Research*, **2004**, 10, 828-39	12.9	211
291	Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. *PLoS Genetics*, **2013**, 9, e1003212	6	209
290	RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. *American Journal of Human Genetics*, **2007**, 81, 1186-200	11	204
289	Counselling framework for moderate-penetrance cancer-susceptibility mutations. *Nature Reviews Clinical Oncology*, **2016**, 13, 581-8	19.4	200
288	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. *Nature Genetics*, **2017**, 49, 680-691	36.3	190
287	Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy. *Gynecologic Oncology*, **2016**, 140, 199-203	4.9	188
286	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. *Nature Genetics*, **2017**, 49, 1767-1778	36.3	186
285	Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. *Lancet Oncology, The*, **2007**, 8, 26-34	21.7	186
284	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. *Nature Genetics*, **2015**, 47, 164-71	36.3	177
283	NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2020**, 18, 380-391	7.3	171
282	A Phase I-II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline -Mutated Ovarian Carcinoma or Other Solid Tumors. *Clinical Cancer Research*, **2017**, 23, 4095-4106	12.9	164
281	Lymphomas of the breast: primary and secondary involvement. *Cancer*, **2002**, 94, 6-13	6.4	164

280	Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study. *European Urology*, **2014**, 66, 489-99	10.2	156
279	Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers. *Journal of the National Cancer Institute*, **2017**, 109,	9.7	153
278	Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA Mutations. *JAMA Oncology*, **2016**, 2, 1434-1440	13.4	151
277	Application of breast cancer risk prediction models in clinical practice. *Journal of Clinical Oncology*, **2003**, 21, 593-601	2.2	150
276	Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. *Cancer Research*, **2010**, 70, 9742-54	10.1	147
275	Adjuvant Olaparib for Patients with - or -Mutated Breast Cancer. *New England Journal of Medicine*, **2021**, 384, 2394-2405	59.2	145
274	BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers. *Nature Communications*, **2017**, 8, 319	17.4	139
273	Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy. *Breast Cancer Research and Treatment*, **2010**, 121, 389-98	4.4	139
272	Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. *Human Mutation*, **2018**, 39, 593-620	4.7	138
271	Modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: systematic review and meta-analysis. *Journal of the National Cancer Institute*, **2014**, 106, dju091	9.7	134
270	Cancer Risks Associated With Germline Pathogenic Variants: An International Study of 524 Families. *Journal of Clinical Oncology*, **2020**, 38, 674-685	2.2	133
269	Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2021**, 19, 77-102	7.3	131
268	Variants at 6q21 implicate PRDM1 in the etiology of therapy-induced second malignancies after Hodgkin lymphoma. *Nature Medicine*, **2011**, 17, 941-3	50.5	128
267	A Population-Based Study of Genes Previously Implicated in Breast Cancer. *New England Journal of Medicine*, **2021**, 384, 440-451	59.2	115
266	Predictors of skeletal complications in patients with metastatic breast carcinoma. *Cancer*, **2000**, 89, 363-8	6.4	111
265	Conflicting Interpretation of Genetic Variants and Cancer Risk by Commercial Laboratories as Assessed by the Prospective Registry of Multiplex Testing. *Journal of Clinical Oncology*, **2016**, 34, 4071-4078	2.2	110
264	Factors determining dissemination of results and uptake of genetic testing in families with known BRCA1/2 mutations. *Genetic Testing and Molecular Biomarkers*, **2008**, 12, 81-91		107
263	Biallelic deleterious BRCA1 mutations in a woman with early-onset ovarian cancer. *Cancer Discovery* , **2013**, 3, 399-405	24.4	106

262	Prevalence of mutations in a panel of breast cancer susceptibility genes in BRCA1/2-negative patients with early-onset breast cancer. *Genetics in Medicine*, **2015**, 17, 630-8	8.1	101
261	Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores. *Journal of Clinical Oncology*, **2017**, 35, 2240-2250	2.2	101
260	Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study. *Lancet Oncology, The*, **2020**, 21, 1155-1164	21.7	98
259	Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. *Nature Genetics*, **2016**, 48, 374-86	36.3	93
258	The relative contribution of point mutations and genomic rearrangements in BRCA1 and BRCA2 in high-risk breast cancer families. *Cancer Research*, **2008**, 68, 7006-14	10.1	92
257	TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes. *Journal of Clinical Oncology*, **2020**, 38, 4274-4282	2.2	92
256	Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. *Human Molecular Genetics*, **2009**, 18, 4442-56	5.6	91
255	Identification of a BRCA2-specific modifier locus at 6p24 related to breast cancer risk. *PLoS Genetics*, **2013**, 9, e1003173	6	90
254	BRCA Challenge: BRCA Exchange as a global resource for variants in BRCA1 and BRCA2. *PLoS Genetics*, **2018**, 14, e1007752	6	90
253	Evaluation of ACMG-Guideline-Based Variant Classification of Cancer Susceptibility and Non-Cancer-Associated Genes in Families Affected by Breast Cancer. *American Journal of Human Genetics*, **2016**, 98, 801-817	11	86
252	Health Care Segregation, Physician Recommendation, and Racial Disparities in BRCA1/2 Testing Among Women With Breast Cancer. *Journal of Clinical Oncology*, **2016**, 34, 2610-8	2.2	83
251	PALB2 mutations in familial breast and pancreatic cancer. *Familial Cancer*, **2011**, 10, 225-31	3	82
250	BRCA1 R1699Q variant displaying ambiguous functional abrogation confers intermediate breast and ovarian cancer risk. *Journal of Medical Genetics*, **2012**, 49, 525-32	5.8	82
249	Telomerase-specific T-cell immunity in breast cancer: effect of vaccination on tumor immunosurveillance. *Cancer Research*, **2007**, 67, 10546-55	10.1	79
248	Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers. *European Urology*, **2019**, 76, 831-842	10.2	78
247	A classification model for BRCA2 DNA binding domain missense variants based on homology-directed repair activity. *Cancer Research*, **2013**, 73, 265-75	10.1	77
246	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. *Nature Genetics*, **2020**, 52, 572-581	36.3	76
245	Common genetic variants and modification of penetrance of BRCA2-associated breast cancer. *PLoS Genetics*, **2010**, 6, e1001183	6	74

244	Interplay between BRCA1 and RHAMM regulates epithelial apicobasal polarization and may influence risk of breast cancer. *PLoS Biology*, **2011**, 9, e1001199	9.7	73
243	Bilateral prophylactic oophorectomy and bilateral prophylactic mastectomy in a prospective cohort of unaffected BRCA1 and BRCA2 mutation carriers. *Clinical Breast Cancer*, **2007**, 7, 875-82	3	69
242	Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk - Combined Results from Two Screening Trials. *Clinical Cancer Research*, **2017**, 23, 3628-3637	12.9	68
241	Risk of ipsilateral breast cancer in BRCA1 and BRCA2 mutation carriers. *Breast Cancer Research and Treatment*, **2011**, 127, 287-96	4.4	66
240	Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. *Nature Communications*, **2016**, 7, 11375	17.4	64
239	Population Frequency of Germline BRCA1/2 Mutations. *Journal of Clinical Oncology*, **2016**, 34, 4183-4185	2.2	64
238	A genome-wide association study of breast cancer in women of African ancestry. *Human Genetics*, **2013**, 132, 39-48	6.3	63
237	Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. *Human Molecular Genetics*, **2011**, 20, 3304-21	5.6	62
236	Development of a tiered and binned genetic counseling model for informed consent in the era of multiplex testing for cancer susceptibility. *Genetics in Medicine*, **2015**, 17, 485-92	8.1	60
235	Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation. *British Journal of Cancer*, **2020**, 122, 333-339	8.7	60
234	Arginine-Nitric Oxide Metabolites and Cardiac Dysfunction in Patients With Breast Cancer. *Journal of the American College of Cardiology*, **2017**, 70, 152-162	15.1	59
233	Evaluation of 19 susceptibility loci of breast cancer in women of African ancestry. *Carcinogenesis*, **2012**, 33, 835-40	4.6	59
232	Noninvasive Measures of Ventricular-Arterial Coupling and Circumferential Strain Predict Cancer Therapeutics-Related Cardiac Dysfunction. *JACC: Cardiovascular Imaging*, **2016**, 9, 1131-1141	8.4	59
231	Low rates of acceptance of BRCA1 and BRCA2 test results among African American women at increased risk for hereditary breast-ovarian cancer. *Genetics in Medicine*, **2006**, 8, 576-82	8.1	58
230	Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. *Breast Cancer Research*, **2016**, 18, 15	8.3	58
229	Cancer treatment according to BRCA1 and BRCA2 mutations. *Nature Reviews Clinical Oncology*, **2012**, 9, 520-8	19.4	56
228	Common variants associated with breast cancer in genome-wide association studies are modifiers of breast cancer risk in BRCA1 and BRCA2 mutation carriers. *Human Molecular Genetics*, **2010**, 19, 2886-97	5.6	56
227	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. *Nature Genetics*, **2020**, 52, 56-73	36.3	56

226	Long-term reactions to genetic testing for BRCA1 and BRCA2 mutations: does time heal women's concerns?. *Journal of Clinical Oncology*, **2011**, 29, 4302-6	2.2	55
225	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. *Nature Communications*, **2016**, 7, 12675	17.4	53
224	Utilizing Remote Real-Time Videoconferencing to Expand Access to Cancer Genetic Services in Community Practices: A Multicenter Feasibility Study. *Journal of Medical Internet Research*, **2016**, 18, e23	7.6	53
223	Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classification. *Human Mutation*, **2019**, 40, 1557-1578	4.7	52
222	The use of the Gail model, body mass index and SNPs to predict breast cancer among women with abnormal (BI-RADS 4) mammograms. *Breast Cancer Research*, **2015**, 17, 1	8.3	52
221	Satisfaction with genetic counseling for BRCA1 and BRCA2 mutations among African American women. *Patient Education and Counseling*, **2006**, 63, 196-204	3.1	48
220	Prophylactic oophorectomy in women at increased cancer risk. *Current Opinion in Obstetrics and Gynecology*, **2007**, 19, 27-30	2.4	47
219	Reproductive Decision-Making in Women with BRCA1/2 Mutations. *Journal of Genetic Counseling*, **2017**, 26, 594-603	2.5	46
218	Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. *Breast Cancer Research*, **2014**, 16, 3416	8.3	46
217	Changes in Cardiovascular Biomarkers With Breast Cancer Therapy and Associations With Cardiac Dysfunction. *Journal of the American Heart Association*, **2020**, 9, e014708	6	44
216	Patient feedback and early outcome data with a novel tiered-binned model for multiplex breast cancer susceptibility testing. *Genetics in Medicine*, **2016**, 18, 25-33	8.1	44
215	Modification of BRCA1-Associated Breast and Ovarian Cancer Risk by BRCA1-Interacting Genes. *Cancer Research*, **2011**, 71, 5792-805	10.1	44
214	Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. *Cancer Epidemiology Biomarkers and Prevention*, **2012**, 21, 645-57	4	44
213	Occult ovarian cancers identified at risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA1/2 mutation carriers. *Breast Cancer Research and Treatment*, **2010**, 124, 195-203	4.4	44
212	Use of risk-reducing surgeries in a prospective cohort of 1,499 BRCA1 and BRCA2 mutation carriers. *Breast Cancer Research and Treatment*, **2014**, 148, 397-406	4.4	42
211	Large prospective study of ovarian cancer screening in high-risk women: CA125 cut-point defined by menopausal status. *Cancer Prevention Research*, **2011**, 4, 1401-8	3.2	42
210	Knowledge, attitudes, and utilization of BRCA1/2 testing among women with early-onset breast cancer. *Genetic Testing and Molecular Biomarkers*, **2005**, 9, 48-53		42
209	Recruiting African American women to participate in hereditary breast cancer research. *Journal of Clinical Oncology*, **2005**, 23, 7967-73	2.2	42

208	Quantitative assessment of background parenchymal enhancement in breast MRI predicts response to risk-reducing salpingo-oophorectomy: preliminary evaluation in a cohort of BRCA1/2 mutation carriers. *Breast Cancer Research*, **2015**, 17, 67	8.3	41
207	Olaparib for Metastatic Germline BRCA-Mutated Breast Cancer. *New England Journal of Medicine*, **2017**, 377, 1792-3	59.2	39
206	Stumbling blocks on the path to personalized medicine in breast cancer: the case of PARP inhibitors for BRCA1/2-associated cancers. *Cancer Discovery*, **2011**, 1, 29-34	24.4	39
205	Predicting BRCA1 and BRCA2 gene mutation carriers: comparison of PENN II model to previous study. *Familial Cancer*, **2010**, 9, 495-502	3	39
204	Genomic Signatures Predict the Immunogenicity of BRCA-Deficient Breast Cancer. *Clinical Cancer Research*, **2019**, 25, 4363-4374	12.9	38
203	Collapse of the CD27+ B-cell compartment associated with systemic plasmacytosis in patients with advanced melanoma and other cancers. *Clinical Cancer Research*, **2009**, 15, 4277-87	12.9	38
202	Age at first birth and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. *Breast Cancer Research and Treatment*, **2007**, 105, 221-8	4.4	38
201	Association of a Polygenic Risk Score With Breast Cancer Among Women Carriers of High- and Moderate-Risk Breast Cancer Genes. *JAMA Network Open*, **2020**, 3, e208501	10.4	38
200	Risk of metachronous breast cancer after BRCA mutation-associated ovarian cancer. *Cancer*, **2013**, 119, 1344-8	6.4	37
199	Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers. *Journal of the National Cancer Institute*, **2011**, 103, 105-16	9.7	37
198	Telomerase vaccination has no detectable effect on SCID-repopulating and colony-forming activities in the bone marrow of cancer patients. *Experimental Hematology*, **2005**, 33, 1275-80	3.1	37
197	Multiplex genetic testing: reconsidering utility and informed consent in the era of next-generation sequencing. *Genetics in Medicine*, **2015**, 17, 97-8	8.1	36
196	Clinical management of hereditary breast cancer syndromes. *Journal of Mammary Gland Biology and Neoplasia*, **2011**, 16, 17-25	2.4	34
195	Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. *Genetics in Medicine*, **2020**, 22, 1653-1666	8.1	34
194	Genome-wide association studies in women of African ancestry identified 3q26.21 as a novel susceptibility locus for oestrogen receptor negative breast cancer. *Human Molecular Genetics*, **2016**, 25, 4835-4846	5.6	34
193	Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in , , or. *Journal of Clinical Oncology*, **2021**, 39, 2497-2505	2.3	34
192	Contraceptive use and the role of contraceptive counseling in reproductive-aged women with cancer. *Contraception*, **2014**, 90, 79-85	2.5	33
191	DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers. *PLoS Genetics*, **2014**, 10, e1004256	6	33

190	Clinically relevant changes in family history of cancer over time. *JAMA - Journal of the American Medical Association*, **2011**, 306, 172-8	27.4	33
189	A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. *Cancer Research*, **2018**, 78, 5419-5430	10.1	32
188	Association of the variants CASP8 D302H and CASP10 V410I with breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. *Cancer Epidemiology Biomarkers and Prevention*, **2010**, 19, 2859-68	4	32
187	Homeostasis of peripheral FoxP3(+) CD4 (+) regulatory T cells in patients with early and late stage breast cancer. *Cancer Immunology, Immunotherapy*, **2010**, 59, 599-607	7.4	32
186	Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. *Human Mutation*, **2012**, 33, 690-702	4.7	31
185	A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale. *Future Oncology*, **2017**, 13, 307-320	3.6	30
184	Impact of shortages of injectable oncology drugs on patient care. *American Journal of Health-System Pharmacy*, **2014**, 71, 571-8	2.2	30
183	Low rates of African American participation in genetic counseling and testing for BRCA1/2 mutations: racial disparities or just a difference?. *Journal of Genetic Counseling*, **2012**, 21, 676-83	2.5	30
182	Adjuvant ovarian function suppression and cognitive function in women with breast cancer. *British Journal of Cancer*, **2016**, 114, 956-64	8.7	30
181	A Recurrent ERCC3 Truncating Mutation Confers Moderate Risk for Breast Cancer. *Cancer Discovery* , **2016**, 6, 1267-1275	24.4	30
180	Dose-response effects of aerobic exercise on estrogen among women at high risk for breast cancer: a randomized controlled trial. *Breast Cancer Research and Treatment*, **2015**, 154, 309-18	4.4	29
179	A functionally significant SNP in TP53 and breast cancer risk in African-American women. *Npj Breast Cancer*, **2017**, 3, 5	7.8	29
178	Understanding participation by African Americans in cancer genetics research. *Journal of the National Medical Association*, **2012**, 104, 324-30	2.3	29
177	Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy. *Journal of Clinical Oncology*, **2018**, 36, 3134-3143	2.2	29
176	Breast MRI fibroglandular volume and parenchymal enhancement in BRCA1 and BRCA2 mutation carriers before and immediately after risk-reducing salpingo-oophorectomy. *American Journal of Roentgenology*, **2015**, 204, 669-73	5.4	28
175	Evaluation of Germline Genetic Testing Criteria in a Hospital-Based Series of Women With Breast Cancer. *Journal of Clinical Oncology*, **2020**, 38, 1409-1418	2.2	28
174	Melanoma genetic testing, counseling, and adherence to skin cancer prevention and detection behaviors. *Cancer Epidemiology Biomarkers and Prevention*, **2013**, 22, 607-14	4	28
173	Therapeutic approaches for women predisposed to breast cancer. *Annual Review of Medicine*, **2011**, 62, 295-306	17.4	28

172	Comprehensive Assessment of Changes in Left Ventricular Diastolic Function With Contemporary Breast Cancer Therapy. *JACC: Cardiovascular Imaging*, **2020**, 13, 198-210	8.4	28
171	Modification of ovarian cancer risk by BRCA1/2-interacting genes in a multicenter cohort of BRCA1/2 mutation carriers. *Cancer Research*, **2009**, 69, 5801-10	10.1	27
170	Evaluation of established breast cancer risk factors as modifiers of BRCA1 or BRCA2: a multi-center case-only analysis. *Breast Cancer Research and Treatment*, **2010**, 124, 441-51	4.4	27
169	Baseline Immunoglobulin E Levels as a Marker of Doxorubicin- and Trastuzumab-Associated Cardiac Dysfunction. *Circulation Research*, **2016**, 119, 1135-1144	15.7	27
168	Assessing associations between the AURKA-HMMR-TPX2-TUBG1 functional module and breast cancer risk in BRCA1/2 mutation carriers. *PLoS ONE*, **2015**, 10, e0120020	3.7	26
167	Contribution of Germline Predisposition Gene Mutations to Breast Cancer Risk in African American Women. *Journal of the National Cancer Institute*, **2020**, 112, 1213-1221	9.7	25
166	Characterization of the Cancer Spectrum in Men With Germline BRCA1 and BRCA2 Pathogenic Variants: Results From the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). *JAMA Oncology*, **2020**, 6, 1218-1230	13.4	25
165	Randomized Noninferiority Trial of Telephone vs In-Person Disclosure of Germline Cancer Genetic Test Results. *Journal of the National Cancer Institute*, **2018**, 110, 985-993	9.7	25
164	Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women. *Breast Cancer Research*, **2016**, 18, 112	8.3	25
163	Breast and ovarian cancer risk and risk reduction in Jewish BRCA1/2 mutation carriers. *Journal of Clinical Oncology*, **2012**, 30, 1321-8	2.2	25
162	Breast cancer screening behaviors among African American women with a strong family history of breast cancer. *Preventive Medicine*, **2006**, 43, 385-8	4.3	25
161	An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in patients with relapsed gastric cancer.. *Journal of Clinical Oncology*, **2019**, 37, 140-140	2.2	25
160	Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. *Breast Cancer Research*, **2016**, 18, 64	8.3	25
159	Long-term risk of medical conditions associated with breast cancer treatment. *Breast Cancer Research and Treatment*, **2014**, 145, 233-43	4.4	24
158	Fine mapping of breast cancer genome-wide association studies loci in women of African ancestry identifies novel susceptibility markers. *Carcinogenesis*, **2013**, 34, 1520-8	4.6	24
157	Combination Paclitaxel and Palbociclib: Results of a Phase I Trial in Advanced Breast Cancer. *Clinical Cancer Research*, **2019**, 25, 2072-2079	12.9	24
156	RE: Breast Cancer Risk After Salpingo-Oophorectomy in Healthy BRCA1/2 Mutation Carriers: Revisiting the Evidence for Risk Reduction. *Journal of the National Cancer Institute*, **2015**, 107,	9.7	23
155	Smoking and the risk of breast cancer in BRCA1 and BRCA2 carriers: an update. *Breast Cancer Research and Treatment*, **2009**, 114, 127-35	4.4	23

154	Childhood cancer in families with and without BRCA1 or BRCA2 mutations ascertained at a high-risk breast cancer clinic. *Cancer Biology and Therapy*, **2006**, 5, 1098-102	4.6	23
153	Association of Genomic Domains in and with Prostate Cancer Risk and Aggressiveness. *Cancer Research*, **2020**, 80, 624-638	10.1	22
152	An international survey of surveillance schemes for unaffected BRCA1 and BRCA2 mutation carriers. *Breast Cancer Research and Treatment*, **2016**, 157, 319-327	4.4	22
151	Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study. *Journal of the National Cancer Institute*, **2019**, 111, 350-364	9.7	22
150	Exercise-Induced Dose-Response Alterations in Adiponectin and Leptin Levels Are Dependent on Body Fat Changes in Women at Risk for Breast Cancer. *Cancer Epidemiology Biomarkers and Prevention*, **2016**, 25, 1195-200	4	21
149	The tubal hypothesis of ovarian cancer: caution needed. *Lancet Oncology, The*, **2011**, 12, 1089-91	21.7	21
148	Challenges to the development of new agents for molecularly defined patient subsets: lessons from BRCA1/2-associated breast cancer. *Journal of Clinical Oncology*, **2011**, 29, 4224-6	2.2	21
147	Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriers. *Human Molecular Genetics*, **2011**, 20, 4732-47	5.6	21
146	Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. *Cancer Epidemiology Biomarkers and Prevention*, **2015**, 24, 308-16	4	20
145	A counseling framework for moderate-penetrance colorectal cancer susceptibility genes. *Genetics in Medicine*, **2018**, 20, 1324-1327	8.1	20
144	Use of systemic hormone therapy in BRCA mutation carriers. *Menopause*, **2016**, 23, 1026-7	2.5	20
143	Quality of life in long-term survivors of metastatic breast cancer. *Clinical Breast Cancer*, **2012**, 12, 119-263		20
142	A nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers. *Cancer Epidemiology Biomarkers and Prevention*, **2012**, 21, 1362-70	4	20
141	Bilateral risk-reducing oophorectomy in BRCA1 and BRCA2 mutation carriers. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2006**, 4, 177-82	7.3	20
140	Towards controlled terminology for reporting germline cancer susceptibility variants: an ENIGMA report. *Journal of Medical Genetics*, **2019**, 56, 347-357	5.8	19
139	Identifying Health Information Technology Needs of Oncologists to Facilitate the Adoption of Genomic Medicine: Recommendations From the 2016 American Society of Clinical Oncology Omics and Precision Oncology Workshop. *Journal of Clinical Oncology*, **2017**, 35, 3153-3159	2.2	19
138	Alcohol consumption and the risk of breast cancer among BRCA1 and BRCA2 mutation carriers. *Breast*, **2010**, 19, 479-83	3.6	19
137	Are physician recommendations for BRCA1/2 testing in patients with breast cancer appropriate? A population-based study. *Cancer*, **2013**, 119, 3596-603	6.4	18

136	Women In Steady Exercise Research (WISER) Sister: study design and methods. *Contemporary Clinical Trials*, **2015**, 41, 17-30	2.3	17
135	CDH1 on Multigene Panel Testing: Look Before You Leap. *Journal of the National Cancer Institute*, **2020**, 112, 330-334	9.7	17
134	BRCA1 and BRCA2 pathogenic sequence variants in women of African origin or ancestry. *Human Mutation*, **2019**, 40, 1781-1796	4.7	16
133	Development and Validation of a Clinical Polygenic Risk Score to Predict Breast Cancer Risk. *JCO Precision Oncology*, **2020**, 4,	3.6	16
132	Splicing profile by capture RNA-seq identifies pathogenic germline variants in tumor suppressor genes. *Npj Precision Oncology*, **2020**, 4, 4	9.8	16
131	Reversion Mutations with Clinical Use of PARP Inhibitors: Many Genes, Many Versions. *Cancer Discovery*, **2017**, 7, 937-939	24.4	16
130	An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. *Breast Cancer Research*, **2015**, 17, 61	8.3	16
129	Follow-up frequency and compliance in women with probably benign findings on breast magnetic resonance imaging. *Academic Radiology*, **2012**, 19, 406-11	4.3	16
128	Genetic variation in IGF2 and HTRA1 and breast cancer risk among BRCA1 and BRCA2 carriers. *Cancer Epidemiology Biomarkers and Prevention*, **2011**, 20, 1690-702	4	16
127	Differential lysis of tumors by polyclonal T cell lines and T cell clones specific for hTERT. *Cancer Biology and Therapy*, **2007**, 6, 1991-6	4.6	16
126	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. *Gynecologic Oncology*, **2016**, 141, 386-401	4.9	15
125	Loss-of-function variants in CTNNA1 detected on multigene panel testing in individuals with gastric or breast cancer. *Genetics in Medicine*, **2020**, 22, 840-846	8.1	15
124	Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. *Breast Cancer Research and Treatment*, **2017**, 161, 117-134	4.4	15
123	Haplotype structure in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers. *Human Genetics*, **2011**, 130, 685-99	6.3	15
122	Multimodal assessment of protein functional deficiency supports pathogenicity of BRCA1 p.V1688del. *Cancer Research*, **2009**, 69, 7030-7	10.1	15
121	Refining Breast Cancer Risk Stratification: Additional Genes, Additional Information. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2016**, 35, 44-56	7.1	15
120	Risk-Reducing Mastectomy in BRCA1 and BRCA2 Mutation Carriers: A Complex Discussion. *JAMA - Journal of the American Medical Association*, **2019**, 321, 27	27.4	15
119	Frequency of radiation-induced malignancies post-adjuvant radiotherapy for breast cancer in patients with Li-Fraumeni syndrome. *Breast Cancer Research and Treatment*, **2020**, 181, 181-188	4.4	14

118	Earlier Colorectal Cancer Screening May Be Necessary In Patients With Li-Fraumeni Syndrome. *Gastroenterology*, **2019**, 156, 273-274	13.3	14
117	Broad Application of Multigene Panel Testing for Breast Cancer Susceptibility-Pandoraâ Box Is Opening Wider. *JAMA Oncology*, **2019**,	13.4	13
116	Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers. *British Journal of Cancer*, **2019**, 121, 180-192	8.7	13
115	Psychosocial Adjustment and Perceived Risk Among Adolescent Girls From Families With BRCA1/2 or Breast Cancer History. *Journal of Clinical Oncology*, **2016**, 34, 3409-16	2.2	13
114	Common genetic variation at BARD1 is not associated with breast cancer risk in BRCA1 or BRCA2 mutation carriers. *Cancer Epidemiology Biomarkers and Prevention*, **2011**, 20, 1032-8	4	13
113	The clinical management of BRCA1 and BRCA2 mutation carriers. *Current Oncology Reports*, **2008**, 10, 47-53	6.3	13
112	Risk factors for sexual dysfunction in BRCA mutation carriers after risk-reducing salpingo-oophorectomy. *Menopause*, **2019**, 26, 132-139	2.5	13
111	Associations between breast density and a panel of single nucleotide polymorphisms linked to breast cancer risk: a cohort study with digital mammography. *BMC Cancer*, **2015**, 15, 143	4.8	12
110	The :p.Arg658* truncating variant is associated with risk of triple-negative breast cancer. *Npj Breast Cancer*, **2019**, 5, 38	7.8	12
109	Lack of association between common single nucleotide polymorphisms in the TERT-CLPTM1L locus and breast cancer in women of African ancestry. *Breast Cancer Research and Treatment*, **2012**, 132, 341-5	4.4	12
108	DCIS in BRCA1 and BRCA2 mutation carriers: prevalence, phenotype, and expression of oncodrivers C-MET and HER3. *Journal of Translational Medicine*, **2015**, 13, 335	8.5	12
107	Tamoxifen and the risk of ovarian cancer in BRCA1 mutation carriers. *Gynecologic Oncology*, **2009**, 115, 135-137	4.9	12
106	Refining Breast Cancer Risk Stratification: Additional Genes, Additional Information. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2016**, 36, 44-56	7.1	12
105	Endoscopic Ultrasound Has Limited Utility in Diagnosis of Gastric Cancer in Carriers of CDH1 Mutations. *Clinical Gastroenterology and Hepatology*, **2020**, 18, 505-508.e1	6.9	12
104	Risk of Breast Cancer Among Carriers of Pathogenic Variants in Breast Cancer Predisposition Genes Varies by Polygenic Risk Score. *Journal of Clinical Oncology*, **2021**, 39, 2564-2573	2.2	12
103	Research participantsÞexperiences with return of genetic research results and preferences for web-based alternatives. *Molecular Genetics & Genomic Medicine*, **2019**, 7, e898	2.3	11
102	Physical and psychological health in rare cancer survivors. *Journal of Cancer Survivorship*, **2017**, 11, 158-165	3.1	11
101	A phase II open-label, multicenter study of single-agent rucaparib in the treatment of patients with relapsed ovarian cancer and a deleterious BRCA mutation.. *Journal of Clinical Oncology*, **2015**, 33, 5513-5513	2.2	11

100	Retrospective Survival Analysis of Patients With Advanced Pancreatic Ductal Adenocarcinoma and Germline or Mutations.. *JCO Precision Oncology*, **2018**, 2, 1-9	3.6	11
99	Preventive surgery is associated with reduced cancer risk and mortality in women with BRCA1 and BRCA2 mutations. *LDI Issue Brief*, **2010**, 16, 1-4		11
98	Association of premenopausal risk-reducing salpingo-oophorectomy with breast cancer risk in BRCA1/2 mutation carriers: Maximising bias-reduction. *European Journal of Cancer*, **2020**, 132, 53-60	7.5	10
97	Ethical Implications of Direct-to-Consumer Hereditary Cancer Tests. *JAMA Oncology*, **2018**, 4, 1327-1328	13.4	10
96	Breast cancer risk and 6q22.33: combined results from Breast Cancer Association Consortium and Consortium of Investigators on Modifiers of BRCA1/2. *PLoS ONE*, **2012**, 7, e35706	3.7	10
95	No evidence that GATA3 rs570613 SNP modifies breast cancer risk. *Breast Cancer Research and Treatment*, **2009**, 117, 371-9	4.4	10
94	Genetic susceptibility to type 2 diabetes and breast cancer risk in women of European and African ancestry. *Cancer Epidemiology Biomarkers and Prevention*, **2012**, 21, 552-6	4	10
93	The prevention of hereditary breast cancer. *Seminars in Oncology*, **2007**, 34, 401-5	5.5	10
92	Recent advances in breast cancer biology. *Current Opinion in Oncology*, **2002**, 14, 589-93	4.2	10
91	A randomized phase II trial of niraparib plus either nivolumab or ipilimumab in patients with advanced pancreatic cancer whose cancer has not progressed on platinum-based therapy.. *Journal of Clinical Oncology*, **2019**, 37, TPS4161-TPS4161	2.2	10
90	Transcriptome-wide association study of breast cancer risk by estrogen-receptor status. *Genetic Epidemiology*, **2020**, 44, 442-468	2.6	9
89	Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition. *British Journal of Cancer*, **2018**, 118, 266-276	8.7	9
88	Panel testing for inherited susceptibility to breast, ovarian, and colorectal cancer. *Genetics in Medicine*, **2014**, 16, 827-9	8.1	9
87	Incremental impact of breast cancer SNP panel on risk classification in a screening population of white and African American women. *Breast Cancer Research and Treatment*, **2013**, 138, 889-98	4.4	9
86	No evidence that CDKN1B (p27) polymorphisms modify breast cancer risk in BRCA1 and BRCA2 mutation carriers. *Breast Cancer Research and Treatment*, **2009**, 115, 307-13	4.4	9
85	Identification and Confirmation of Potentially Actionable Germline Mutations in Tumor-Only Genomic Sequencing. *JCO Precision Oncology*, **2019**, 3,	3.6	9
84	How Should Patients and Providers Interpret the US Food and Drug Administration's Regulatory Language for Direct-to-Consumer Genetic Tests?. *Journal of Clinical Oncology*, **2019**, 37, 2514-2517	2.2	8
83	Breast cancer surgery trend changes since the introduction of BRCA1/2 mutation screening: a retrospective cohort analysis of 158 mutation carriers treated at a single institution. *Annals of Surgical Oncology*, **2011**, 18, 745-51	3.1	8

82	Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer. *Gynecologic Oncology*, **2021**, 163, 246-253	4.9	8
81	Preferences for in-person disclosure: Patients declining telephone disclosure characteristics and outcomes in the multicenter Communication Of GENetic Test Results by Telephone study. *Clinical Genetics*, **2019**, 95, 293-301	4	8
80	Returning Individual Genetic Research Results to Research Participants: Uptake and Outcomes Among Patients With Breast Cancer. *JCO Precision Oncology*, **2018**, 2,	3.6	8
79	Integrating Clinical and Polygenic Factors to Predict Breast Cancer Risk in Women Undergoing Genetic Testing. *JCO Precision Oncology*, **2021**, 5,	3.6	8
78	Detailed phenotyping reveals distinct trajectories of cardiovascular function and symptoms with exposure to modern breast cancer therapy. *Cancer*, **2019**, 125, 2762-2771	6.4	7
77	Breast cancer gene variants: separating the harmful from the harmless. *Journal of Clinical Investigation*, **2009**, 119, 2895-7	15.9	7
76	A Rare Mutation Predominant in Ashkenazi Jews Confers Risk of Multiple Cancers. *Cancer Research*, **2020**, 80, 3732-3744	10.1	7
75	Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. *PLoS ONE*, **2016**, 11, e0158801	3.7	7
74	Comparison of the Prevalence of Pathogenic Variants in Cancer Susceptibility Genes in Black Women and Non-Hispanic White Women With Breast Cancer in the United States. *JAMA Oncology*, **2021**, 7, 1045-1050	13.4	7
73	Familial Breast Cancer Risk. *Current Breast Cancer Reports*, **2013**, 5, 170-182	0.8	6
72	Large genomic rearrangement in BRCA1 and BRCA2 and clinical characteristics of men with breast cancer in the United States. *Clinical Breast Cancer*, **2007**, 7, 627-33	3	6
71	Germline Pathogenic Variants in Cancer Predisposition Genes Among Women With Invasive Lobular Carcinoma of the Breast. *Journal of Clinical Oncology*, **2021**, 39, 3918-3926	2.2	6
70	Cardiovascular Function Phenotypes in Response to Cardiotoxic Breast Cancer Therapy. *Journal of the American College of Cardiology*, **2019**, 73, 248-249	15.1	6
69	Rapid detection of recurrent mutations in Chinese breast and ovarian cancer patients with multiplex SNaPshot genotyping panels. *Oncotarget*, **2018**, 9, 7832-7843	3.3	6
68	Relationship of established risk factors with breast cancer subtypes. *Cancer Medicine*, **2021**, 10, 6456-6467	4.8	6
67	RE: BRCA1 and BRCA2 Gene Mutations and Colorectal Cancer Risk: Systematic Review and Meta-analysis. *Journal of the National Cancer Institute*, **2019**, 111, 522-523	9.7	5
66	Agreement of self-reported hormone receptor status with cancer registry data in young breast cancer patients. *Cancer Epidemiology*, **2013**, 37, 601-5	2.8	5
65	Ten-fold increase in genetic testing in pancreatic and metastatic prostate cancer with implementation of point of care (POC) testing.. *Journal of Clinical Oncology*, **2019**, 37, 1506-1506	2.2	5

64	Real-world integration of genomic data into the electronic health record: the PennChart Genomics Initiative. *Genetics in Medicine*, **2021**, 23, 603-605	8.1	5
63	Clinical Characteristics of Patients With Pancreatic Cancer and Pathogenic Alterations. *JNCI Cancer Spectrum*, **2021**, 5, pkaa121	4.6	5
62	Uptake of BRCA 1/2 and oncotype DX testing by medical and surgical oncologists. *Breast Cancer Research and Treatment*, **2018**, 171, 173-180	4.4	4
61	Clinical implications of low-penetrance breast cancer susceptibility alleles. *Current Oncology Reports*, **2009**, 11, 8-14	6.3	4
60	How genetic variant libraries effectively extend gene testing patents: implications for intellectual property and good clinical care. *Journal of Clinical Oncology*, **2012**, 30, 2943-5	2.2	4
59	Utilization of religious coping strategies among African American women at increased risk for hereditary breast and ovarian cancer. *Family and Community Health*, **2009**, 32, 218-27	1.6	4
58	Executive function after risk-reducing salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: does current mood and early life adversity matter?. *Menopause*, **2020**, 27, 746-755	2.5	4
57	The contemporary landscape of genetic testing and breast cancer: Emerging issues. *Breast Journal*, **2020**, 26, 1549-1555	1.2	4
56	Randomized study of remote telehealth genetic services versus usual care in oncology practices without genetic counselors. *Cancer Medicine*, **2021**, 10, 4532-4541	4.8	4
55	A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. *Nature Communications*, **2021**, 12, 1078	17.4	4
54	Integrating Genetic and Genomic Testing Into Oncology Practice. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2020**, 40, e259-e263	7.1	3
53	Longitudinal outcomes with cancer multigene panel testing in previously tested BRCA1/2 negative patients. *Clinical Genetics*, **2020**, 97, 601-609	4	3
52	A single arm phase II study of rucaparib maintenance in patients with advanced pancreatic adenocarcinoma and a known deleterious BRCA1, BRCA2 or PALB2 mutation who have achieved stability on platinum therapy.. *Journal of Clinical Oncology*, **2018**, 36, TPS531-TPS531	2.2	3
51	Cancer risk models: translating family history into clinical management. *Annals of Internal Medicine*, **2007**, 147, 515-7	8	3
50	Association of germline variation with the survival of women with pathogenic variants and breast cancer. *Npj Breast Cancer*, **2020**, 6, 44	7.8	3
49	Upper Gastrointestinal Cancer Risk and Surveillance Outcomes in Li-Fraumeni Syndrome. *American Journal of Gastroenterology*, **2020**, 115, 2095-2097	0.7	3
48	What happens after menopause? (WHAM): A prospective controlled study of depression and anxiety up to 12 months after premenopausal risk-reducing bilateral salpingo-oophorectomy. *Gynecologic Oncology*, **2021**, 161, 527-534	4.9	3
47	Risk of Late-Onset Breast Cancer in Genetically Predisposed Women. *Journal of Clinical Oncology*, **2021**, 39, 3430-3440	2.2	3

46	Pervasive genetic testing. *Lancet, The*, **2018**, 391, 2089-2091	40	3
45	Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores. *Journal of the National Cancer Institute*, **2021**,	9.7	3
44	Risks of breast and ovarian cancer for women harboring pathogenic missense variants in BRCA1 and BRCA2 compared with those harboring protein truncating variants.. *Genetics in Medicine*, **2021**,	8.1	2
43	Mutation Rates in Cancer Susceptibility Genes in Patients With Breast Cancer With Multiple Primary Cancers. *JCO Precision Oncology*, **2020**, 4,	3.6	2
42	Challenges and Opportunities in Engaging Primary Care Providers in BRCA Testing: Results from the BFOR Study. *Journal of General Internal Medicine*, **2021**, 1	4	2
41	Comprehensive Breast Cancer Risk Assessment for and Pathogenic Variant Carriers Incorporating a Polygenic Risk Score and the Tyrer-Cuzick Model. *JCO Precision Oncology*, **2021**, 5,	3.6	2
40	The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant. *Genetics in Medicine*, **2021**, 23, 1726-1737	8.1	2
39	What Happens After Menopause? (WHAM): A prospective controlled study of cardiovascular and metabolic risk 12 months after premenopausal risk-reducing bilateral salpingo-oophorectomy. *Gynecologic Oncology*, **2021**, 162, 88-96	4.9	2
38	Response. *Journal of the National Cancer Institute*, **2016**, 108,	9.7	2
37	Uptake and acceptability of a mainstreaming model of hereditary cancer multigene panel testing among patients with ovarian, pancreatic, and prostate cancer. *Genetics in Medicine*, **2021**, 23, 2105-2113	8.1	2
36	Risk factors for breast cancer subtypes among Black women undergoing screening mammography. *Breast Cancer Research and Treatment*, **2021**, 189, 827-835	4.4	2
35	Longitudinal follow-up after telephone disclosure in the randomized COGENT study. *Genetics in Medicine*, **2020**, 22, 1401-1406	8.1	1
34	Reply to R.L. Nussbaum et al and J.S. Dolinsky et al. *Journal of Clinical Oncology*, **2017**, 35, 1262-1263	2.2	1
33	Refining BRCA1 and BRCA2 penetrance estimates in the clinic. *Current Breast Cancer Reports*, **2009**, 1, 127-130	0.8	1
32	Characteristics of high risk breast cancer patients with mutations identified by multiplex panel testing.. *Journal of Clinical Oncology*, **2015**, 33, 1511-1511	2.2	1
31	Patterns and predictors of BRCA 1/2 testing in young breast cancer survivors.. *Journal of Clinical Oncology*, **2016**, 34, 1514-1514	2.2	1
30	Prospective registry of multiplex testing (PROMPT): A web-based platform to assess cancer risk of genetic variants.. *Journal of Clinical Oncology*, **2016**, 34, 1518-1518	2.2	1
29	Targeted BRCA1/2 population screening among Ashkenazi Jewish individuals using a web-enabled medical model: An observational cohort study.. *Genetics in Medicine*, **2021**,	8.1	1

28	Germline genetic testing for breast cancer: which patients? What genes?. *Genetics in Medicine*, **2020**, 22, 698-700	8.1	1
27	What happens after menopause? (WHAM): A prospective controlled study of vasomotor symptoms and menopause-related quality of life 12 months after premenopausal risk-reducing salpingo-oophorectomy. *Gynecologic Oncology*, **2021**, 163, 148-154	4.9	1
26	Preventative Health and Risk Behaviors Among Adolescent Girls With and Without Family Histories of Breast Cancer. *Journal of Adolescent Health*, **2019**, 64, 116-123	5.8	1
25	A prospective controlled study of sexual function and sexually related personal distress up to 12 months after premenopausal risk-reducing bilateral salpingo-oophorectomy. *Menopause*, **2021**, 28, 748-755	2.5	1
24	The evolution of poly(ADP-ribose) polymerase inhibitors in the treatment of breast cancer. *Clinical Advances in Hematology and Oncology*, **2018**, 16, 330-332	0.6	1
23	Cancer susceptibility mutations in individuals with breast and ovarian cancer using next-generation sequencing.. *Journal of Clinical Oncology*, **2016**, 34, 1515-1515	2.2	0
22	EUS-based Pancreatic Cancer Surveillance in Carriers Without a Family History of Pancreatic Cancer. *Cancer Prevention Research*, **2021**, 14, 1033-1040	3.2	0
21	What happens after menopause? (WHAM): A prospective controlled study of sleep quality up to 12 months after premenopausal risk-reducing salpingo-oophorectomy. *Gynecologic Oncology*, **2021**, 162, 447-453	4.9	0
20	Mutations and Cardiovascular Function in Breast Cancer Survivors.. *Frontiers in Cardiovascular Medicine*, **2022**, 9, 833171	5.4	0
19	Loss and Promoter Hypermethylation Negatively Predict for Immunogenicity in BRCA-Deficient Ovarian Cancer.. *JCO Precision Oncology*, **2022**, 6, e2100159	3.6	0
18	Prophylactic Mastectomy and Risk-Reducing Salpingo-oophorectomy in BRCA1/2 Mutation Carriers. *Current Breast Cancer Reports*, **2012**, 4, 199-206	0.8	
17	Breast Reconstruction A Historical Perspective on Available Techniques for Patients Electing Bilateral Mastectomy. *Current Cancer Therapy Reviews*, **2011**, 7, 272-281	0.4	
16	EMR documentation of genetics evaluations in patients with ovarian cancer.. *Journal of Clinical Oncology*, **2019**, 37, e13156-e13156	2.2	
15	Genetic predisposition to breast cancer among African American women.. *Journal of Clinical Oncology*, **2019**, 37, 104-104	2.2	
14	Comprehensive breast cancer (BC) risk assessment for CHEK2 carriers incorporating a polygenic risk score (PRS) and the Tyrer-Cuzick (TC) model.. *Journal of Clinical Oncology*, **2020**, 38, 1504-1504	2.2	
13	Current Insights: Evolving Principles and Controversies of Cancer Risk Assessment and Management of Hereditary Cancers. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2020**, 18, 964-967	7.3	
12	Interest in and outcomes with return of individual genetic research results for inherited susceptibility to breast cancer.. *Journal of Clinical Oncology*, **2015**, 33, e12503-e12503	2.2	
11	Information preferences of women with triple-negative breast cancer (TNBC).. *Journal of Clinical Oncology*, **2015**, 33, e20585-e20585	2.2	

10	Meeting the educational needs of women with triple-negative breast cancer (TNBC).. *Journal of Clinical Oncology*, **2015**, 33, e20580-e20580	2.2
9	Uterine cancer (Ut Ca) following risk-reducing salpingo-oophorectomy (RRSO) in women with BRCA mutations (BRCA+): A multicenter, prospective study.. *Journal of Clinical Oncology*, **2015**, 33, 1504-1504	2.2
8	Patient-reported outcomes in a multicenter randomized study of in-person versus telephone disclosure of genetic test results for cancer susceptibility.. *Journal of Clinical Oncology*, **2016**, 34, 1502-1502	2.2
7	Identification of genetic test results with conflicting interpretations in prospective registry of multiplex testing (PROMPT).. *Journal of Clinical Oncology*, **2016**, 34, 1510-1510	2.2
6	Extended follow-up in the COGENT study: A randomized study of in-person versus telephone disclosure of cancer genetic test results.. *Journal of Clinical Oncology*, **2017**, 35, 1504-1504	2.2
5	Knowledge outcomes in a randomized trial of telephone vs. in-person disclosure of genetic testing: The COGENT study.. *Journal of Clinical Oncology*, **2017**, 35, 1534-1534	2.2
4	Reply to Patel and McLeod. *Journal of Clinical Oncology*, **2020**, 38, 284	2.2
3	Abstract OT2-18-01: Harnessing olaparib, palbociclib, and endocrine therapy (HOPE): Phase I/II trial of olaparib, palbociclib and fulvestrant in patients with BRCA1/2-associated, hormone receptor-positive, HER2-negative metastatic breast cancer. *Cancer Research*, **2022**, 82, OT2-18-01-OT2-18-01	10.1
2	Abstract P2-09-01: Population-based risk estimates of clinical subtypes of breast cancer among carriers of germline pathogenic variants in cancer predisposition genes. *Cancer Research*, **2022**, 82, P2-09-01-P2-09-01	10.1
1	Abstract P2-11-21: Integration of an ancestrally unbiased polygenic risk score with the Tyrer-Cuzick breast cancer risk model. *Cancer Research*, **2022**, 82, P2-11-21-P2-11-21	10.1